Xtant Medical Q4 revenue up 9% to $15.3M; full year net loss widens to $8.5M

Xtant Medical Holdings, Inc.

Q4 revenue $15.3M, up 9% YoY; full year revenue $58.0M, up 5% YoY.
Q4 net loss $2.2M ($0.02 per share), vs $2.3M ($0.03) in prior year.
Full year net loss $8.5M ($0.09 per share), up from $4.8M ($0.06) in 2021.
Non-GAAP Adjusted EBITDA full year loss $3.0M vs gain $0.3M in 2021.
Acquired Coflex product line to enhance fixation offering; financial details not disclosed.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.7

Xtant Medical Holdings, Inc. reported the fourth quarter and year ended December 31, 2022 results: revenue $15.3 million, net income $0.02 per share, EPS $0.02 per share.

Period: the fourth quarter and year ended December 31, 2022
Revenue: $15.3 million
Net income: $0.02 per share
EPS: $0.02 per share
Result: reported results

Exact text from the filing

network, all of which are core focus areas to our long-term growth strategy.” Fourth Quarter and Full Year 2022 Financial Results Fourth quarter 2022 revenue grew 9% to $15.3 million, compared to $14.0 million for the same quarter in 2021. Full year 2022 revenue was $58.0 million, compared to $55.3 million for 2021. The increase in revenue was largely

View on SEC.gov

Browse all earnings releases →

Xtant Medical Holdings, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-23-006880

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.